Study design
The OCEANIC-STROKE study was a multicenter, randomized, placebo-controlled, double-blind, and event-driven phase 3 study designed to demonstrate the efficacy and safety of SUNHARBO® (50 mg once daily) in combination with antiplatelet therapy (APT) for the prevention of ischemic stroke in adults 18 years or older after an index event of acute non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥6). Patients were randomized within 72 hours after onset of symptoms.1
ABCD2=Age, Blood Pressure, Clinical Features, Duration, and Diabetes.